ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 404

The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis

David S. Pisetsky1,2, Diane Spencer3, Stephen R. Wisniewski4, Jason Lyons4, Melissa Saul5, Mandy J. McGeachy6, Yong Gil Hwang7, Heather Eng4 and Larry W. Moreland6, 1Medical Research Service, Durham VAMC, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Medicine, Duke University Medical Center, Durham, NC, 4Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 5Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 6Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Department of Medicine, University of Pittsburgh, Pittsburgh, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose

HMGB1 (High Mobility Group Box 1), a non-histone nuclear protein, is a prototypic alarmin that displays immunological activity following release during cell death or immune cell activation.  As shown in studies of patients with rheumatoid arthritis (RA) and animal models, HMGB1 plays a key role in pathogenesis; HMGB1 has increased expression in synovial tissue and blockade of HMGB1 can attenuate disease in animal models.  While the role of HMGB1 in mediating disease has been well studied, its role as a biomarker has received less attention. The present study therefore explored the expression of HMGB1 in the blood of RA patients, investigating correlations with various clinical features.

Methods

This study utilized samples from the RACER (Rheumatoid Arthritis Comparative Effectiveness Research) cohort.  Patients varied in disease duration and received therapy determined by clinical response.  Disease activity was assessed by DAS 28 scores using C-reactive protein as the acute phase reactant.  The samples, selected to provide a range of disease activity, were divided into 4 groups:  remission; low activity; moderate activity; and high activity. Levels of HMGB1 were determined by ELISA using the Shino-test kit. The concentrations of HMGB1 in the plasma from 10, non-RA control subjects were also measured.

Results

Among 100 patients with RA, HMGB1 levels varied from 1.1 to 19.3 ng/ml (median value = 5.73 ng/ml) which was significantly higher than those of the control population (range = 0.72-3.28; median value = 1.93 ng/ml).  Despite the increase in HMGB1 levels in the RA population, the median values of the 4 disease activity groups were similar (remission, 5.98; low 5.09; moderate 5.64; high, 6.02).  These differences did not reach statistical significance by a non-parametric ANOVA.  In contrast, CRP levels showed a statistically significant association with disease activity by a non-parametric ANOVA (<0.0001).   As a previous study suggested a relationship with disease duration, the results were analyzed in terms of duration less than 5 years, 5-10 years, 15-20 years and greater than 20 years.  This analysis failed to reveal a relationship with disease duration.  Values of males and females were also similar.   

Conclusion

These studies demonstrate that levels of HMGB1 are elevated in the blood of patients with RA and show a relationship to disease activity distinct from that of CRP.  As HMGB1 levels were increased in patients either in remission or with low disease activity, these findings suggest ongoing inflammation that may not be apparent with either the DAS 28 or CRP.  Furthermore, since HMGB1 can also arise from cell death, the elevation of HMGB1 levels, even with remission or low disease activity, may reflect tissue destruction that persists even with inflammation restrained.


Disclosure:

D. S. Pisetsky,
None;

D. Spencer,
None;

S. R. Wisniewski,
None;

J. Lyons,
None;

M. Saul,
None;

M. J. McGeachy,
None;

Y. G. Hwang,
None;

H. Eng,
None;

L. W. Moreland,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-disease-activity-and-levels-of-hmgb1-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.